252 related articles for article (PubMed ID: 20970422)
1. Recent advances in the development of immunotherapies for tauopathies.
Ubhi K; Masliah E
Exp Neurol; 2011 Aug; 230(2):157-61. PubMed ID: 20970422
[TBL] [Abstract][Full Text] [Related]
2. Tau immunotherapy for Alzheimer's disease.
Pedersen JT; Sigurdsson EM
Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies.
Rosenmann H
Curr Alzheimer Res; 2013 Mar; 10(3):217-28. PubMed ID: 23534533
[TBL] [Abstract][Full Text] [Related]
4. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
[TBL] [Abstract][Full Text] [Related]
5. Tau Proteins and Tauopathies in Alzheimer's Disease.
Chong FP; Ng KY; Koh RY; Chye SM
Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
[TBL] [Abstract][Full Text] [Related]
6. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
[TBL] [Abstract][Full Text] [Related]
7. Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.
Schroeder SK; Joly-Amado A; Gordon MN; Morgan D
J Neuroimmune Pharmacol; 2016 Mar; 11(1):9-25. PubMed ID: 26538351
[TBL] [Abstract][Full Text] [Related]
8. Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease.
Madav Y; Wairkar S; Prabhakar B
Brain Res Bull; 2019 Mar; 146():171-184. PubMed ID: 30634016
[TBL] [Abstract][Full Text] [Related]
9. A walk through tau therapeutic strategies.
Jadhav S; Avila J; Schöll M; Kovacs GG; Kövari E; Skrabana R; Evans LD; Kontsekova E; Malawska B; de Silva R; Buee L; Zilka N
Acta Neuropathol Commun; 2019 Feb; 7(1):22. PubMed ID: 30767766
[TBL] [Abstract][Full Text] [Related]
10. Tau Immunotherapy.
Sigurdsson EM
Neurodegener Dis; 2016; 16(1-2):34-8. PubMed ID: 26551002
[TBL] [Abstract][Full Text] [Related]
11. Tau immunotherapies: Lessons learned, current status and future considerations.
Sandusky-Beltran LA; Sigurdsson EM
Neuropharmacology; 2020 Sep; 175():108104. PubMed ID: 32360477
[TBL] [Abstract][Full Text] [Related]
12. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
13. Tau immunotherapy in Alzheimer's disease and progressive supranuclear palsy.
Karimi N; Bayram Çatak F; Arslan E; Saghazadeh A; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt B):109445. PubMed ID: 36410182
[TBL] [Abstract][Full Text] [Related]
14. An Overview on the Clinical Development of Tau-Based Therapeutics.
Medina M
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641484
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.
Sigurdsson EM
J Alzheimers Dis; 2008 Oct; 15(2):157-68. PubMed ID: 18953105
[TBL] [Abstract][Full Text] [Related]
16. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.
Sigurdsson EM
Curr Alzheimer Res; 2009 Oct; 6(5):446-50. PubMed ID: 19874269
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in tau-based therapeutics for neurodegenerative diseases.
Medina M
Recent Pat CNS Drug Discov; 2011 Jan; 6(1):20-30. PubMed ID: 21118095
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for tauopathies.
Gu J; Sigurdsson EM
J Mol Neurosci; 2011 Nov; 45(3):690-5. PubMed ID: 21739165
[TBL] [Abstract][Full Text] [Related]
19. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
[TBL] [Abstract][Full Text] [Related]
20. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
